Overview
Pfizer Polska focuses on vaccines and the development of oncology therapies for frequently occurring and difficult-to-treat cancers. The company traces its origins to a chemical enterprise founded in New York in the mid-19th century by Charles Pfizer and Charles Erhardt.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $870,668 |
Filing timeliness
Financial statements were filed on time, on average 42 days early. All were audited by a statutory auditor.
- 202526/05/2026
- 202429/05/2025
- 202320/05/2024
- 202226/04/2023
- 202119/05/2022
- 202024/05/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
- Advertising agencies (73.11.Z) Primary
Offer
- Vaccines
- Oncology medicines
- Therapeutic treatments
Websites
The company has 6 websites.
- pfizer.plStrona główna | Pfizer | PolskaLinkedIn AdsCloudflare
- kleszcze.info.plWszystko o kleszczach, chorobach odkleszczowych i szczepieniachLinkedIn AdsCloudflare
- pfizerpro.plStrona główna | PfizerProLinkedIn AdsCloudflare
Public procurement
2 tenders recorded as contractor: 1 national ($84,860) and 1 EU ($234,699).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 10, 2025 | Supply of medicinal products from drug programmes and various medicinal products | $234.7K$234,699 | Copernicus Podmiot Leczniczy sp. z o.o. | |
| Oct 1, 2021 | Supply of medicinal products – lorlatinibum, dacomitinibum | $84,860$84,860 | Centrum Onkologii Im. Prof. Franciszka Łukaszczyka w Bydgoszczy |
Pfizer Polska has been a party to 2 cases before the National Appeal Chamber (since 2018).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Feb 6, 2020 | Tender evaluation criteria | Dismissed | Zakład Zamówień Publicznych przy Ministrze Zdrowia | |
| Oct 18, 2018 | Tender evaluation criteria | Dismissed | Zakład Zamówień Publicznych przy Ministrze Zdrowia z siedzibą w Warszawie |
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2003.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| DLA ZDECYDOWANYCH NA RZUCENIE PALENIA (word) | Z.268049 | 5, 10, 30 | Proceedings discontinued | – |
| Mark | Protected until | |
|---|---|---|
| DLA ZDECYDOWANYCH NA RZUCENIE PALENIA (word) | – |
Authorized Representatives
Manner of representation
The President of the Management Board is authorized to submit declarations and sign on behalf of the company independently, whereas, in the case of a multi-member management board, the President of the Management Board independently, or two other members of the management board acting jointly, or a member of the management board acting jointly with a commercial proxy are authorized to do so.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Pfizer Luxembourg Sarl | 33,860 | $9,146,407.35 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Pfizer Inc. (United States) group. Its direct owner is Pfizer Luxembourg S.à r.l (Luxembourg). The group has 149 companies, 146 of them abroad.
| Name | Country |
|---|---|
| Pfizer Trading Polska | |
| "Pfizer Corporation Austria" Gesellschaft M.B.H. | |
| AHP Holdings BV | |
| AHP Manufacturing B.V. | |
| C.P. Pharmaceuticals International C.V. |
Bank accounts
Registered as a VAT taxpayer on 2003-11-30.
57 1030 1508 0000 0005 0079 7045
79 1030 1508 0000 0005 0079 7037
51 1030 1335 0000 0005 0079 7500
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 300.6KPLN 300,603 |
MSiG notices
10 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Aug 11, 2020 | Return of additional payments | |
| Aug 31, 2016 | Commercial Companies Code notice | |
| Jul 21, 2014 | Commercial Companies Code notice | |
| Oct 2, 2013 | Commercial Companies Code notice | |
| Feb 24, 2012 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Novartis Poland sp. z o.o. | $378,147,128.47 | novartis.com | ||
| MSD Polska Dystrybucja sp. z o.o. | $341,786,056.16 | msd.pl | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Astellas Pharma sp. z o.o. | $220,199,081.58 | astellas.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Amgen sp. z o.o. | $145,068,009.51 | amgen.pl | ||
| Ipsen Poland sp. z o.o. | $94,814,847.87 | ipsen.com | ||
| Magnapharm Poland sp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Pierre Fabre Medicament Polska . sp. z o.o. | $87,306,127.57 | pierre-fabre.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-11-09 | PKD change (Removed: 63.99.Z, 69.20.Z, 72.11.Z; Added: 63.92.Z, 69.20.A, 72.10.Z) | |
| 2018-09-13 | Address change (Postępu 17b, 02-676, Warszawa → Ul. Żwirki I Wigury 16b, 02-092, Warszawa) | |
| 2012-08-03 | Share capital reduction (73,860,000.00 PLN → 33,860,000.00 PLN) | |
| 2011-03-28 | Share capital increase (17,860,000.00 PLN → 73,860,000.00 PLN) | |
| 2010-10-29 | Address change (Rzymowskiego 28, 02-697, Warszawa → Postępu 17b, 02-676, Warszawa) |
FAQ
Last updated: 2026-11-09